A Phase I Clinical Trial of T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Anti SLAMF7 chimeric antigen receptor T cell therapy (Primary) ; Cyclophosphamide; Fludarabine; Rimiducid
- Indications Multiple myeloma; Plasmacytoma
- Focus Adverse reactions
Most Recent Events
- 20 Jan 2021 Status changed from recruiting to completed.
- 20 Jun 2020 Planned number of patients changed from 42 to 36.
- 25 Jun 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 27 Jun 2019 to 1 Jul 2019.